Tuberc Respir Dis.
2004 Jul;57(1):32-36.
Diagnostic Utility of Pleural Fluid CEA and CYFRA 21-1 for Malignant Pleural Effusions
- Affiliations
-
- 1Department of Internal Medicine, Kwandong University College of Medicine, Myungji Hospital, Koyang, Korea.
- 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. sekyukim@yumc.yonsei.ac.kr
- 3The Institute of Chest Diseases, Yonsei University College of Medicine, Seoul, Korea.
- 4Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
- 5Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea.
Abstract
-
BACKGROUND: The purpose of this study was to evaluate the usefulness of the pleural fluid carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) tumor markers as complementary tools for the diagnosis of malignant pleural effusions.
PATIENTS AND METHODS
The levels of pleural and serum CEA and CYFRA 21-1 were prospectively assayed in 222 patients with pleural effusions (150 benign effusions, 57 bronchogenic carcinomas and 15 metastatic carcinomas).
RESULTS
The levels of pleural fluid CEA and CYFRA 21-1 in the malignant effusions were significantly higher than those in the benign effusions. With a specificity of 95%, the cut off values for the CEA and CYFRA 21-1 in pleural effusions were 5 and 89 ng/ml, respectively. The diagnostic sensitivities of the pleural fluid CEA and CYFRA 21-1 in malignant effusions were 72 and 54%, respectively, whereas using a combination of the two, the sensitivity increased to 87% (p<0.05).
CONCLUSIONS
: These findings suggest that a combination of the pleural fluid CEA and CYFRA 21-1 in pleural effusions can be useful in the diagnosis of malignant pleural effusions.